Skip to main content
. Author manuscript; available in PMC: 2010 Oct 22.
Published in final edited form as: Liver Transpl. 2005 Nov;11(11):1343–1352. doi: 10.1002/lt.20536

Figure 1.

Figure 1

Patient and graft survival (months). Patient (black diamonds) and graft (gray squares) survival to three years for HCV-infected liver recipients (top panels) and uninfected recipients (bottom panels) under the TAC-PRED and ATG-TAC immunosuppression regimens. The P values calculated by log-rank between the charts show that all other survival results were similar except in HCV-positive recipients under ATG-TAC immunosuppression. The current mean serum bilirubin of surviving primary grafts in the different groups (subscripts) is not significantly different. Horizontal axis in months.